A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.

被引：0
|
作者：
Kudgus, R. A. [1 ]
Fox, E. [2 ]
McGovern, R. M. [1 ]
Moorthy, G. [2 ]
Marachelian, A. [3 ]
DuBois, S. G. [4 ]
Reid, J. M. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-031
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [1] Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory neuroblastoma.
    Zhu, Jia
    Zhen, Zijun
    Wang, Juan
    Chen, Tingting
    Lu, Suying
    Sun, Feifei
    Huang, Junting
    Que, Yi
    Zhang, Lian
    Zhang, Yizhuo
    Sun, Xiaofei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
    DuBois, Steven G.
    Mosse, Yael P.
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    McGovern, Renee
    Groshen, Susan
    Bagatell, Rochelle
    Maris, John M.
    Twist, Clare J.
    Goldsmith, Kelly
    Granger, M. Meaghan
    Weiss, Brian
    Park, Julie R.
    Macy, Margaret E.
    Cohn, Susan L.
    Yanik, Greg
    Wagner, Lars M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Luo, Chunqiao
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Marachelian, Araz
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6142 - 6149
  • [3] Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    Kushner, Brian H.
    Kramer, Kim
    Modak, Shakeel
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) : 5271 - 5276
  • [4] Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
    DuBois, Steven G.
    Marachelian, Araz
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    Groshen, Susan G.
    Malvar, Jemily
    Bagatell, Rochelle
    Wagner, Lars M.
    Maris, John M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Tsao-Wei, Denice D.
    Matthay, Katherine K.
    Mosse, Yael P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
    Zhu, Jia
    Wang, Juan
    Sun, Feifei
    Zhen, Zijun
    Chen, Tingting
    Lu, Suying
    Huang, Junting
    Zhang, Yizhuo
    Sun, Xiaofei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
    Bagatell, Rochelle
    London, Wendy B.
    Wagner, Lars M.
    Voss, Stephan D.
    Stewart, Clinton F.
    Maris, John M.
    Kretschmar, Cynthia
    Cohn, Susan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 208 - 213
  • [7] Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
    DuBois, Steven G.
    Marachelian, Araz
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    Groshen, Susan
    Malvar, Jemily
    Bagatell, Rochelle
    Wagner, Lars
    Maris, John M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Czarnecki, Scarlett
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Mosse, Yael P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1368 - +
  • [8] Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
    Modak, Shakeel
    Kushner, Brian H.
    Basu, Ellen
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (08)
  • [9] VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma
    Setty, Bhuvana A.
    Stanek, Joseph R.
    Mascarenhas, Leo
    Miller, Alexandra
    Bagatell, Rochelle
    Okcu, Fatih
    Nicholls, Lauren
    Lysecki, David
    Gupta, Abha A.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (01)
  • [10] Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB).
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Leyco, Samantha
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345